Patients taking GLP-1 drugs like Wegovy and Ozempic are facing new barriers. Some states, such as Pennsylvania, are restricting Medicaid coverage for these medications, while studies are exploring alternative approaches to their use, including reduced dosing and new formulations like oral pills. The impact of these developments on patient access and treatment outcomes is still being assessed.